top of page

Today, Monday 24 June 2024, has taken a closer look at a very interesting Swedish biotechnology company.

[24 June 2024]

Today, Monday 24 June 2024, has taken a closer look at a very interesting Swedish biotechnology company, BioInvent International AB (Ticker on Nasdaq Stockholm: BINV). is not alone in having faith in this share, and the share is among other things in Pareto's Swedish share portfolio, and recently on 07 June Van Lanschot Kempen (Kempen) repeated theirs buy recommendation on BioInvent and raised theirs price target for the share to SEK 55 (from previously SEK 30).


First a little about BioInvent International AB (ticker at Nasdaq Stockholm: BINV)

BioInvent is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programmes in Phase I/II trials for the treatment of haematological cancer and solid tumours, respectively and a fifth program just initiating clinical development.

BioInvent’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering.

BioInvent generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the company’s fully integrated manufacturing unit.

The head office is located in Lund, Sweden.

Read more about the company on their website here:



[24 June 2024 - MFN] BioInvent får godkänt patent för BI-1808 i Kina

Lund, Sweden - June 24, 2024 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notice of allowance, informing the company that a patent application relating to the anti-TNFR2 antibody BI-1808 will be granted.

The patent provides composition-of matter protection for BI-1808 and the use of the antibody for the treatment of cancer.

"We are developing the next generation of immuno-oncology cancer treatments and the granting of this patent for BI-1808 is an important milestone in ensuring we robustly protect our innovative products.

BI-1808 has already demonstrated encouraging signals of efficacy in the ongoing clinical evaluation in solid tumors and we look forward to progressing the antibody in clinical development," said Martin Welschof, Chief Executive Officer of BioInvent.

"We place great value on the protection of our intellectual property as an intrinsic part of the development of our unique cancer immunotherapy pipeline and our overall business strategy."

Read the full stock exchange announcement here:


Technical Analysis of BioInvent International AB (ticker at Nasdaq Stockholm: BINV):

Charts are from the technical analysis program Vikingen.

The BioInvent share is showing strong development within a steeply rising trend, and further growth is signaled for the share in both the short and medium term. The share is consolidating in the very short picture after breaking above an important technical resistance level around SEK 32.00 (cf. weekly chart). The stock is now consolidating between SEK 32.00 and SEK 38.00 and believes a break up from this consolidation formation may come within a short time. This will trigger a new technical buy signal for the share. Various momentum indicators such as RSI and Stochastics indicate that the stock may face further upswing in the short term. On the upside, there is some technical resistance around the SEK 38.00 level, but then there will be little technical resistance until up to the SEK 50.00 level. On the downside, there is significant technical support around the SEK 32.00 level and around the 50-day moving average at the SEK 30.00 level.'s own analysis models, The SignalList and The TradingList, are both now in a buy signal for the BioInvent share. The overall technical picture for the BioInvent share is therefore positive, and further growth is signaled for the share in both the short and medium term. sees a short-term (1-3 months) potential for the stock at around SEK 50.00.


NB! Remember to have read and understood the disclaimer.


Commenting has been turned off.
bottom of page